Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in chronic heart failure with significant coronary artery disease after hospitalization for worsening heart failure
NL-OMON44917Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) and coronary arteriosclerosis comparing Rivaroxaban plus standard care with Placebo plus standard care (2 arms). Primary endpoint: Composite of all-cause mortality, myocardial infarction, or stroke. Started Feb 2014; status: active, not recruiting.
02
Drugs
rivaroxaban
03
Conditions
heart failure (HF)coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON44917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44917.